LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

QuidelOrtho Highlights Innovative Point-of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 21 May 2023
Image: The Savanna automated sample-to-result multiplex RT-PCR testing platform (Photo courtesy of QuidelOrtho)
Image: The Savanna automated sample-to-result multiplex RT-PCR testing platform (Photo courtesy of QuidelOrtho)

QuidelOrtho Corporation (San Diego, CA, USA) is highlighting the latest advances in laboratory testing and point-of-care diagnostics at the Euromedlab Congress in Rome. The company is demonstrating how effectively combining point-of-care and laboratory testing can enhance patient care and improve overall healthcare outcomes. QuidelOrtho’s advanced lab management tools and expertise can help labs streamline their workflow, automate operations, and efficiently analyze data, thereby enhancing overall efficiency without compromising on quality.

At EuroMedLab Rome 2023, the company is demonstrating Savanna – a true sample-to-result point-of-care multiplex molecular solution. The cutting-edge system can accurately and simultaneously test for SARS-CoV-2, Flu A, Flu B, and RSV on a panel within 20 minutes. Besides delivering rapid results, the RVP4 also delivers superior clinical performance and possesses the capability to detect SARS-CoV-2 variants. Additionally, QuidelOrtho is demonstrating how its Vitros XT 7600 Integrated System can boost lab efficiency, offering a wide-ranging menu of over 160 assays, thus future-proofing labs and preparing them for potential Vitros Automation incorporation. This system is also time-efficient, with a first-pass yield of 96.5% and incorporates E-Connectivity Technology for uninterrupted operation. The company's innovative waterless system further maximizes lab space and enhances productivity.

Among QuidelOrtho’s innovative point-of-care solutions being featured at the industry event is the TriageTrue High Sensitivity Troponin I Test. This revolutionary test empowers medical professionals to make informed decisions that lead to better patient outcomes and overall improved healthcare efficiency. The test merges ER and lab testing, delivering high diagnostic precision with results available in under 20 minutes. The quick results can expedite patient handling, minimize hospital stay duration, and enhance ED throughput. In addition, QuidelOrtho is participating in the Euromedlab 2023 Satellite Meeting - Point-of-Care Testing: Home, Hospital and Beyond event. The company’s Vendor Talk by Dr. Holger Gundelach, Head of EMEA POC-IA Business Unit and Clinical Value at QuidelOrtho, on "The time is now – Accelerate patient management at the point-of-care" will be providing valuable insights and exploring the future of point-of-care testing.

Related Links:
QuidelOrtho Corporation 

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more